Skip to content

Direct Oral Challenges in Private Practice Setting to Delabeling Children With Beta-lactam Allergy

Feasibility of Direct Oral Challenges in Private Practice Setting for the Evaluation of Mild Delayed Reactions to Beta-lactams in Children

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07002814
Acronym
Betalactaville
Enrollment
200
Registered
2025-06-04
Start date
2026-06-01
Completion date
2027-06-01
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Keywords

Beta-lactams, Allerg, Allergology, Direct oral challenge

Brief summary

The purpose of this study is to demonstrate the feasibility of direct oral challenge performed in private practice setting for children with suspected benign delayed allergy to beta-lactams. The results of this study could help establish recommendations for conducting direct oral challenge in primary care settings to delabeling children with benign delayed reactions to beta-lactams.

Detailed description

Approximately 10% of children are labeled as allergic to beta-lactams (BL). Consequently, they receive alternative antibiotics with a broader spectrum but lower efficacy, leading to increased infectious morbidity and mortality, a higher risk of colonization with antibiotic-resistant bacteria, and elevated healthcare costs. However, true BL allergy is only confirmed in 5-10% of cases. Therefore, an essential challenge is to promptly identify non-allergic children to prevent unnecessary medical restrictions. The most common reactions are delayed and benign. Current guidelines recommend evaluating these reactions through direct oral challenge (DOC) without prior allergological assessment, as traditional diagnostic methods, particularly skin tests, have poor sensitivity in this context. However, the optimal setting for conducting these tests remains debated, particularly regarding whether they can be initiated in hospital settings or private medical practices. To date, over 8,300 DOCs have been performed in children, predominantly in hospital-based consultations. These tests have demonstrated a favorable safety profile, with positive DOC reactions often being of the same nature and less severe than the initial reported reaction. While many physicians perform DOCs in private practice, data on their use in pediatric populations remain scarce. The primary objective of this study is to assess the feasibility of DOCs conducted in private medical practices for children with suspected benign delayed allergy to BL

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No

Inclusion criteria

* Population: Children's age between 0 and 17 years * Child who has undergone a direct oral challenge in a private medical practice and a follow-up consultation within 7 to 14 days for suspected delayed allergy to amoxicillin +/- clavulanate or cefpodoxime or cefixime with the following characteristics: * delayed reaction (onset \> 1 hour after treatment start), * mild reaction (isolated urticaria or Maculopapular exanthema), * Absence of warning signs suggestive of a severe cutaneous adverse reaction (erythroderma, presence of bullae, vesicles, pustules, target lesions, involvement of oral, genital, or ocular mucosa, facial edema, general condition impairment, organ failure, duration \> 7 days).

Exclusion criteria

* Informed children or holders of parental authority objecting to the use of patient data in the study.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of direct oral challenge (DOC) for beta-lactam allergy assessmentDay 14Demonstrate the feasibility of direct oral challenges (DOCs) performed in private medical practices for the evaluation of delayed and benign reactions to beta-lactams in children by collecting the amount of positive and negative DOC results and benign reactions description.

Secondary

MeasureTime frameDescription
Negative and positive tests reaction nature comparisonDay 14Collect and compare the nature of reactions between children with positive and negative direct oral challenge
Negative and positive tests reaction chronology comparisonDay 14Collect and compare chronology of reactions between children with positive and negative direct oral challenge.
Negative and positive tests reaction duration comparisonDay 14Collect and compare duration of reactions between children with positive and negative direct oral challenge.
Negative and positive tests reactions index comparisonDay 14Index reactions between children with positive and negative direct oral challenge.
Reactions nature in positive testsDay 14Collect and analyse the nature of reactions in positive direct oral challenge
Reactions extension in positive testsDay 14Collect and analyse the extension of reactions in positive direct oral challenge
Reactions duration in positive testsDay 14Collect and analyse the duration of reactions in positive direct oral challenge

Countries

France

Contacts

CONTACTSebastien LE, MD
sebastien.le@aphp.fr06 35 14 12 41
CONTACTGael Plastow
gael.plastow@aphp.fr01 44 38 18 57
PRINCIPAL_INVESTIGATORSebastien LE, MD

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026